Septerna, Inc.
No enriched coverage for $SEPN in the last 7 days.
According to an SEC Form 4, Septerna (SEPN) Chief People Officer Samira Shaikhly exercised and sold 11,798 shares of common stock for about $355,000 at a weighted average price of $30.06, leaving 793 shares (~$24,305) after the May 26, 2026 close. The sale followed a Rule 10b5-1 plan and option exercises; Septerna reported $522.1M cash runway into 2029.
Septerna, Inc. (SEPN) said its SEP-479 program advanced: the first comprehensive preclinical characterization was accepted for an ENDO 2026 oral presentation, covering the pharmacology of the selective PTH1R agonist for hypoparathyroidism. The company is running a Phase 1 trial in healthy volunteers, with initial data expected late 2026/early 2027. TheFly reported Guggenheim initiated coverage with a Buy and $52 target.
Septerna, Inc. (SEPN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001984086 0001984086 2026-06-26 2026-06-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26,
Recent SEPN coverage spans financial news, insider activity and technology.
In the last 30 days, SEPN insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($251K). The most active reporter was Long Daniel D., SVP, Drug Discovery, with 2 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Insider selling under a Rule 10b5-1 plan is typically lower-signal, but the large single sale and cadence can still affect near-term sentiment.
ENDO 2026 accepted abstract and Phase 1 timing (late 2026/early 2027) provide incremental clinical-development visibility for SEP-479.
Routine shareholder-meeting outcomes; no new financial guidance, deal, or enforcement action disclosed.
Routine 10b5-1 insider selling; likely limited incremental signal, but can modestly affect near-term sentiment/positioning.
Insider selling under a 10b5-1 plan is typically low-signal; it may modestly affect near-term sentiment but is not a fundamental catalyst.
alphai scores every news story that mentions SEPN with an AI model for sentiment and relevance, and aggregates insider trades from Septerna, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
According to an SEC Form 4, Septerna (SEPN) Chief People Officer Samira Shaikhly exercised and sold 11,798 shares of common stock for about $355,000 at a weighted average price of $30.06, leaving 793 shares (~$24,305) after the May 26, 2026 close. The sale followed a Rule 10b5-1 plan and option exercises; Septerna reported $522.1M cash runway into 2029.
4 min readSepterna, Inc. (SEPN) said its SEP-479 program advanced: the first comprehensive preclinical characterization was accepted for an ENDO 2026 oral presentation, covering the pharmacology of the selective PTH1R agonist for hypoparathyroidism. The company is running a Phase 1 trial in healthy volunteers, with initial data expected late 2026/early 2027. TheFly reported Guggenheim initiated coverage with a Buy and $52 target.
4 min readSepterna, Inc. (SEPN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001984086 0001984086 2026-06-26 2026-06-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26,
3 min readLong Daniel D. (SVP, Drug Discovery) sold 15,000 shares of Septerna, Inc. (SEPN) at an average of $35.51 ($35.10–$35.97, $0.53M total) across 2 trades on 2026-06-22 under a Rule 10b5-1 trading plan.
2 min readShaikhly Samira (Chief People Officer) sold 2,889 shares of Septerna, Inc. (SEPN) at $29.66 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readShaikhly Samira (Chief People Officer) sold 1,346 shares of Septerna, Inc. (SEPN) at $28.79 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readShaikhly Samira (Chief People Officer) sold 1,700 shares of Septerna, Inc. (SEPN) at $27.78 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readSepterna (Nasdaq: SEPN) announced its first-quarter 2026 financial results, reporting a narrowed net loss of $8.6 million and $26.5 million in collaboration revenue. The company highlighted positive Phase 1 clinical data for SEP-631, supporting its advancement into Phase 2b for chronic spontaneous urticaria, and the initiation of a Phase 1 trial for SEP-479 for hypoparathyroidism. Septerna projects its $522.1 million cash reserves will fund operations until at least 2029, even as R&D and G&A expenses increased to support pipeline progress.
3 min readSepterna, Inc. (NASDAQ: SEPN) has issued a definitive proxy statement (DEF 14A) detailing the agenda for its upcoming 2026 Annual Meeting of Stockholders. The virtual-only meeting will be held on June 26, 2026, at 2:00 p.m. Pacific Time, where shareholders will vote on the election of two Class II directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The board of directors recommends voting "FOR" both proposals.
2 min readAnalysts have provided conflicting ratings for several technology stocks. Fortinet (FTNT) received a Hold rating from UBS, with a price target of $90.00, alongside a general consensus of Hold. Septerna, Inc. (SEPN) was reiterated as a Buy by H.C. Wainwright with a $40.00 price target and has a Strong Buy consensus. Oracle (ORCL) maintained a Buy rating from TD Cowen with a $250.00 price target, and generally holds a Strong Buy consensus among analysts.
4 min read
